Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

5 Resultados de la búsqueda.

Thrombosis Registry Oncology Thromboses UK Essen - Thrombosis

- 20.09.21 - 1 formulario, 1 itemgroup, 23 items, 1 idioma

Itemgroup: Thrombosis

Study part: Thrombosis Registry for oncologic patients with thromboses. The aim of the study was to determine the incidence of thrombosis in oncology patients. A register study of University Clinic Essen (UK Essen), permission granted by Claudia Ose from the Center for Clinical Studies Essen (Zentrums für Klinische Studien Essen, ZKSE).

Eligibility Thrombosis Type 2 Diabetes NCT02373332

- 20.06.21 - 1 formulario, 2 itemgroups, 11 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Fatty Acid Regulation of Platelet Function in Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02373332

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 02

- 22.10.18 - 1 formulario, 5 itemgroups, 35 items, 1 idioma

Itemgroups: Experimental Drug, Dosage, Hematology finding, Biochemistry, Venography, Prophylactic treatment, Mechanical Methods; Physical therapy

Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Eligibility Thrombosis NCT00447434

- 29.06.17 - 1 formulario, 2 itemgroups, 34 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Efficacy and Safety of Natto Extract; ODM derived from: https://clinicaltrials.gov/show/NCT00447434

Eligibility NCT00439725 Deep Vein Thrombosis - Eligibility

- 09.12.13 - 1 formulario, 3 itemgroups, 17 items, 2 idiomas

Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts

This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study).

Utilice este formulario para comentarios, preguntas y sugerencias.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.